Guideline for Initial Workup of Suspected Crohn’s Disease

Clinical Assessment

• Obtain a detailed history that includes stool frequency, consistency, and presence of blood, as well as constitutional symptoms (fever, weight loss, malaise) and abdominal pain patterns. The American Gastroenterology Association recommends this comprehensive history as the first step in evaluating suspected Crohn’s disease 1.
• Actively inquire about extra‑intestinal manifestations such as arthritis/arthralgia, uveitis, erythema nodosum, and pyoderma gangrenosum, because their presence supports the diagnosis. The European Crohn’s and Colitis Organisation highlights these manifestations as key diagnostic clues 2, 3.
• Record medication use, especially non‑steroidal anti‑inflammatory drugs (NSAIDs); they should be stopped ≥ 4 weeks before capsule endoscopy to avoid drug‑induced lesions that mimic Crohn’s disease. The Crohn’s & Colitis Society advises this withdrawal period 2, 3.
• Document smoking status and family history of inflammatory bowel disease, as both influence disease risk and phenotype. Guidelines from the American Gastroenterology Association include these risk factors 1.
• Perform a mandatory perianal examination to detect fistulas or abscesses, which are present in up to 27 % of patients at presentation. The American College of Radiology notes the high prevalence of occult perianal disease 4.
• Assess vital signs, weight, and signs of fluid depletion, and conduct an abdominal exam for tenderness, masses, or distension. Standard clinical assessment protocols recommend these examinations 1.

Baseline Laboratory Investigations

• Order a complete blood count to identify anemia, thrombocytosis, or leukocytosis. Guidelines recommend CBC as a core test 1.
• Measure inflammatory markers (ESR and/or CRP); elevated values increase diagnostic yield, especially when combined with anemia. The American Gastroenterology Association cites ESR/CRP as essential inflammatory markers 1, 2.
• Perform a comprehensive metabolic panel (electrolytes, liver function tests) to evaluate nutritional and organ status. Standard work‑up includes metabolic profiling 1.
• Obtain stool studies for bacterial culture and Clostridioides difficile toxin to exclude infectious colitis. Guidelines advise stool testing to rule out mimicking infections 1.

Endoscopic Evaluation

• Ileocolonoscopy with biopsies is the first‑line diagnostic procedure when clinically safe. The American Gastroenterology Association designates ileocolonoscopy as the primary diagnostic tool 1, 5.
• Intubate the terminal ileum and obtain biopsies even if the mucosa appears normal, because microscopic disease may be present. Guidelines emphasize routine ileal intubation 1.
• Take segmental biopsies throughout the colon and use standardized scoring systems to document mucosal findings. The 2025 Gut guideline recommends systematic biopsy sampling and scoring 5.
• Typical endoscopic findings include non‑continuous (skip) lesions; these are characteristic of Crohn’s disease. Endoscopic pattern recognition is highlighted in the 2004 Gut consensus 1.
• Histologic hallmarks are focal, asymmetric, patchy chronic inflammation and, when present, non‑caseating granulomas (pathognomonic but not always observed). Histopathologic criteria are outlined by the American Gastroenterology Association 1.

Small‑Bowel Imaging

MR Enterography (Preferred First‑Line)

• MR enterography is the preferred initial imaging modality because it avoids ionizing radiation. The American College of Radiology recommends MR enterography as the first‑line study 4, 5.
• The protocol requires oral contrast (≈ 900–1 500 mL over 45–60 min) to achieve adequate bowel distention. Technical guidelines specify contrast volume and timing 4.
• Imaging coverage must include the perineum to detect occult perianal disease. Radiology guidelines stress perineal inclusion 4.
• MR enterography evaluates transmural inflammation, strictures, and extraluminal complications (e.g., fistulas, abscesses). The Crohn’s & Colitis Society cites these capabilities 2, 3.

CT Enterography (Alternative)

• CT enterography is appropriate when MR enterography is unavailable, in emergency settings requiring rapid acquisition, or when patients have contraindications to MRI (e.g., implanted devices). The American College of Radiology lists these indications 4.

Small‑Bowel Follow‑Through

• Small‑bowel follow‑through remains an option but provides inferior diagnostic information compared with cross‑sectional imaging. Guidelines favor cross‑sectional modalities over fluoroscopic studies 1.

Plain Abdominal Radiography

• Obtain a plain abdominal X‑ray in patients with suspected severe disease to exclude colonic dilatation, identify small‑bowel dilatation or right iliac fossa masses, and assess disease extent in acute presentations. The 2004 Gut guideline recommends plain radiography for severe presentations 1.

Capsule Endoscopy

• Reserve small‑bowel capsule endoscopy for patients with high clinical suspicion of Crohn’s disease who have negative ileocolonoscopy and imaging studies. The Crohn’s & Colitis Society advises this sequential approach 2, 3, 6, 5.
• Selection criteria: chronic abdominal pain, chronic diarrhea, weight loss + either extra‑intestinal manifestations, elevated inflammatory markers/fecal calprotectin, or abnormal imaging. These criteria are defined in the 2013 Crohn’s & Colitis consensus 2, 3.
• Perform a patency capsule test before capsule endoscopy in patients with obstructive symptoms, prior small‑bowel resection, or known strictures to prevent capsule retention. Guidelines mandate patency assessment in these risk groups 5, 2, 3.
• Capsule endoscopy has a high negative predictive value but lower specificity than cross‑sectional imaging (CT/MR enterography). The diagnostic performance is outlined by the Crohn’s & Colitis Society 2, 3, 6.

Ultrasound

• Intestinal ultrasound, when performed by experienced operators, can identify thickened bowel loops and complications (e.g., strictures, fistulas) but is operator‑dependent. Guidelines acknowledge ultrasound as a useful adjunct in skilled hands 1, 5.

Common Pitfalls & Safety Measures

• Do not omit perianal examination; perianal disease occurs in 13–27 % of all patients and 15–25 % of pediatric patients at presentation. The American College of Radiology highlights this prevalence 4.
• Ensure NSAIDs are withdrawn ≥ 4 weeks before capsule endoscopy to avoid drug‑induced lesions that mimic Crohn’s disease. The Crohn’s & Colitis Society specifies this withdrawal period 2, 3.
• Always perform a patency capsule assessment before capsule endoscopy in patients with obstructive symptoms or known strictures to avoid retention. Guidelines from Gut (2025) stress this precaution 5.
• Include the perineum in imaging protocols to detect occult perianal disease that may be missed on physical exam. Radiology guidelines recommend perineal coverage 4.
• Diagnosis requires integration of clinical history, endoscopic findings, histology, and radiologic imaging; no single test is sufficient. The 2004 Gut consensus emphasizes a multimodal diagnostic approach 1.

Crohn's Disease Diagnosis and Assessment

Clinical Presentation and Diagnostic Approach

• The American Gastroenterological Association recommends that Crohn's disease diagnosis should be based on a combination of clinical presentation, laboratory tests, and endoscopic evaluation, as the disease typically presents with chronic diarrhea, abdominal pain, weight loss, and systemic symptoms including fever and malaise, often accompanied by elevated inflammatory markers 7, 8
• The European Society of Gastrointestinal Endoscopy suggests that diarrhea lasting more than 6 weeks is the hallmark symptom of Crohn's disease, with severe flares producing at least 10 loose stools daily 7, 9
• The American College of Radiology recommends that MR enterography is preferred as first-line imaging because it does not expose patients to ionizing radiation and has similar diagnostic accuracy to CT enterography 8, 10, 11

Diagnostic Tests and Procedures

• The American Gastroenterological Association recommends that fecal calprotectin is a reliable indicator of intestinal inflammation; levels >100 mg/g predict positive findings (43%), with >200 mg/g providing even higher diagnostic yield (65%) 8, 12
• The European Society of Gastrointestinal Endoscopy suggests that ileocolonoscopy with segmental biopsies should be performed when Crohn's disease is suspected and the procedure is clinically safe 8, 11
• The American College of Radiology recommends that CT enterography is appropriate when MR enterography is unavailable or in emergency settings, with short acquisition time (<2 seconds) 10

Disease Activity Assessment and Monitoring

• The American Gastroenterological Association recommends that standardized scoring systems, such as the Crohn's Disease Activity Index (CDAI), should be used to objectively measure disease activity, as symptoms and inflammation can be disconnected 9, 13
• The European Society of Gastrointestinal Endoscopy suggests that inflammation often persists in the absence of gastrointestinal symptoms and may lead to progressive bowel damage and complications such as fistulae, abscesses, and strictures 13

Special Diagnostic Scenarios

• The American Gastroenterological Association recommends that capsule endoscopy should be performed when clinical features are consistent with Crohn's disease but ileocolonoscopy and imaging studies are negative or inconclusive 7, 8, 12
• The European Society of Gastrointestinal Endoscopy suggests that a patency capsule should be used prior to capsule endoscopy in patients with suspected Crohn's disease who have obstructive symptoms, history of small bowel resection, or known stenosis 8, 14, 15